Tuesday, July 26 7 – 8:30 a.m. Marriott Marquis, Grand Horizon Ballroom AB Supported by ABBOTT, Core Diagnostics
One of the most fundamental requirements of the clinical laboratory is to ensure accurate and high-quality test results that advance, diagnose, and/or optimize treatment for patients and communities. With the emerging trends, new diseases, and associated complexities therein, meeting these fundamental needs often requires enhanced awareness and innovative thinking, as well as new evidence-based strategies.
This workshop will highlight relevant evidence that supports the increased use of biotin supplements across the globe while underscoring the associated impact of these trends through published case examples that involve test interference, differences in methodologies, and elevated risks for misdiagnosis across disease areas. Other relevant interferences, such as method differences using hemolyzed samples will also be discussed. Risks have become confounded during the COVID-19 pandemic, as procurement challenges have led to global tube shortages, making accurate and first-pass testing not only crucial, but even more relevant for timely, accurate, and seamless patient care.
By the end of the session, participants should be able to:
Ramani Wondering, MSc, PhD Scientific Affairs ABBOTT, Core Diagnostics North Chicago, IL
Saleh Aldasouqi, MD Professor of Medicine and Chief of the Division of Endocrinology Michigan State University Lansing, MI James Neuenschwander, MD, FACEP, FASAM Attending Emergency Physician, Doctors Hospital Columbus Adjunct Associated Professor, The Ohio State University Columbus, OH
Be the first to get all the latest news.